Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 28, 2015; 21(28): 8660-8669
Published online Jul 28, 2015. doi: 10.3748/wjg.v21.i28.8660
Figure 4
Full Size Figure Download Figure
Figure 4 Sustained virological response by Cirrhosis. A: Sustained virological response (SVR) in cirrhotic patients (n = 69), based on their on-treatment response at week 4, 8 and 12; B: SVR rates in cirrhotics based on their on-treatment responses, comparing Asians (n = 30) vs Caucasians (n = 39). Significant differences are shown.
  • Citation: Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, Totten L, Wigg A, Altus R, Colman A, Morales B, Mason S, Jones T, Leembruggen N, Fragomelli V, Sendall C, Guan R, Sutedja D, Tan SS, Dan YY, Lee YM, Luman W, Teo EK, Than YM, Piratvisuth T, Lim SG. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers. World J Gastroenterol 2015; 21(28): 8660-8669
  • URL: https://www.wjgnet.com/1007-9327/full/v21/i28/8660.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v21.i28.8660